|
2025 Journal Article Metabolic rate and insulin-independent glucose uptake increase in a TDP-43Q331K mouse model of amyotrophic lateral sclerosisMcDonald, Tanya S., Cui, Cedric S., Lerskiatiphanich, Titaya, Marallag, Jianina and Lee, John D. (2025). Metabolic rate and insulin-independent glucose uptake increase in a TDP-43Q331K mouse model of amyotrophic lateral sclerosis. Heliyon, 11 (3) e42482, 1-13. doi: 10.1016/j.heliyon.2025.e42482 |
|
2024 Conference Publication Colon-targeted complement C5aR1 inhibition using pH-sensitive nanoparticles ameliorates experimental colitisCui, Cedric, Lee, John and Woodruff, Trent (2024). Colon-targeted complement C5aR1 inhibition using pH-sensitive nanoparticles ameliorates experimental colitis. 19th European Meeting on Complement in Human Diseases, Lübeck, Germany, 2-6 September 2024. Weinheim, Germany: Wiley-VCH. |
|
2024 Conference Publication Development of novel peptide ligands with improved selectivity and pharmacological properties for complement system receptorsClark, Richard, Gorman, Declan, Li, Xaria, Dent, Joshua, Cui, Cedric, Lee, Han Siean, Fung, Jenny, Lee, John, Rosengren, K. Johan and Woodruff, Trent (2024). Development of novel peptide ligands with improved selectivity and pharmacological properties for complement system receptors. 37th European Peptide Symposium 14th International Peptide Symposium, Florence, Italy, 25-29 August 2024. Oxford, United Kingdom: John Wiley & Sons. |
|
2022 Other Outputs Preclinical development of complement C5aR1 antagonists for the treatment of inflammatory bowel diseaseCui, Shuai (2022). Preclinical development of complement C5aR1 antagonists for the treatment of inflammatory bowel disease. PhD Thesis, School of Biomedical Sciences, The University of Queensland. doi: 10.14264/3a8be04 |
|
2022 Journal Article Success in navigating hurdles to oral delivery of a bioactive peptide complement antagonist through use of nanoparticles to increase bioavailability and in vivo efficacyXu, Weizhi, Kumar, Vinod, Cui, Cedric S., Li, Xaria X., Whittaker, Andrew K., Xu, Zhi Ping, Smith, Maree T., Woodruff, Trent M. and Han, Felicity Y (2022). Success in navigating hurdles to oral delivery of a bioactive peptide complement antagonist through use of nanoparticles to increase bioavailability and in vivo efficacy. Advanced Therapeutics, 5 (12) 2200109, 2200109. doi: 10.1002/adtp.202200109 |
|
2021 Journal Article In vivo pharmacodynamic method to assess complement C5a receptor antagonist efficacyCui, Cedric S., Kumar, Vinod, Gorman, Declan M., Clark, Richard J., Lee, John D. and Woodruff, Trent M. (2021). In vivo pharmacodynamic method to assess complement C5a receptor antagonist efficacy. ACS Pharmacology and Translational Science, 5 (1) acsptsci.1c00227, 41-51. doi: 10.1021/acsptsci.1c00227 |
|
2021 Journal Article Sustained-release ketamine-loaded lipid-particulate system: in vivo assessment in miceXu, Weizhi, Maqbool, Faheem, Kumar, Vinod, Falconer, James R., Cui, Cedric S., Woodruff, Trent M., Borges, Karin, Whittaker, Andrew K., Smith, Maree T. and Han, Felicity Y. (2021). Sustained-release ketamine-loaded lipid-particulate system: in vivo assessment in mice. Drug Delivery and Translational Research, 12 (10), 2518-2526. doi: 10.1007/s13346-021-01093-3 |
|
2021 Journal Article Development of synthetic human and mouse C5a: application to binding and functional assays in vitro and in vivoGorman, Declan M., Li, Xaria X., Payne, Colton D., Cui, Cedric S., Lee, John D., Rosengren, K. Johan, Woodruff, Trent M. and Clark, Richard J. (2021). Development of synthetic human and mouse C5a: application to binding and functional assays in vitro and in vivo. ACS Pharmacology and Translational Science, 4 (6) acsptsci.1c00199, 1808-1817. doi: 10.1021/acsptsci.1c00199 |
|
2021 Journal Article Development of Potent and Selective Agonists for Complement C5a Receptor 1 with In Vivo ActivityGorman, Declan M., Li, Xaria X., Lee, John D., Fung, Jenny N., Cui, Cedric S., Lee, Han Siean, Rolfe, Barbara E., Woodruff, Trent M. and Clark, Richard J. (2021). Development of Potent and Selective Agonists for Complement C5a Receptor 1 with In Vivo Activity. Journal of Medicinal Chemistry, 64 (22) acs.jmedchem.1c01174, 16598-16608. doi: 10.1021/acs.jmedchem.1c01174 |
|
2021 Journal Article Intrinsic bias at non-canonical, β-arrestin-coupled seven transmembrane receptorsPandey, Shubhi, Kumari, Punita, Baidya, Mithu, Kise, Ryoji, Cao, Yubo, Dwivedi-Agnihotri, Hemlata, Banerjee, Ramanuj, Li, Xaria X., Cui, Cedric S., Lee, John D., Kawakami, Kouki, Maharana, Jagannath, Ranjan, Ashutosh, Chaturvedi, Madhu, Jhingan, Gagan Deep, Laporte, Stéphane A., Woodruff, Trent M., Inoue, Asuka and Shukla, Arun K. (2021). Intrinsic bias at non-canonical, β-arrestin-coupled seven transmembrane receptors. Molecular Cell, 81 (22), 4605-4621.e11. doi: 10.1016/j.molcel.2021.09.007 |
|
2021 Journal Article Optimisation of a microfluidic method for the delivery of a small peptideHan, Felicity Y., Xu, Weizhi, Kumar, Vinod, Cui, Cedric S., Li, Xaria, Jiang, Xingyu, Woodruff, Trent M., Whittaker, Andrew K. and Smith, Maree T. (2021). Optimisation of a microfluidic method for the delivery of a small peptide. Pharmaceutics, 13 (9) 1505, 1505. doi: 10.3390/pharmaceutics13091505 |
|
2017 Journal Article CD8+ lineage dendritic cells determine adaptive immune responses to inflammasome activation upon sterile skin injuryChakraborty, Rituparna, Chandra, Janin, Cui, Shuai, Tolley, Lynn, Cooper, Matthew A., Kendall, Mark and Frazer, Ian H. (2017). CD8+ lineage dendritic cells determine adaptive immune responses to inflammasome activation upon sterile skin injury. Experimental Dermatology, 27 (1), 71-79. doi: 10.1111/exd.13436 |
